Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

Posted on July 9, 2026
By International Business Times
0 Views
1 min read

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed to achieve the primary endpoint in a late-stage clinical trial for a rare heart disease.